Total health care costs are significantly higher in women with both uterine fibroids (UFs) and heavy menstrual bleeding (HMB) as opposed to those with only one of these conditions, according to new research to be presented at AMCP Nexus 2019.
Among female patients with symptomatic UF, HMB is one of the most prevalent burdens they face, according to the study abstract. Citing a lack of existing research regarding the economic burden these women with HMB or UF face, these study researchers aimed to compare the health care costs of women with both conditions to those of patients with UF only, HMB only, or neither.
This retrospective cohort study leveraged Truven MarketScan Commercial Claims and Encounters Database information collected from July 2007 to June 2018. Women between ages 18 and 51 were placed in four cohorts based on diagnoses of HMB only (ICD-9-CM 626.2 or 627.0, or ICD-10-CM N92.0, N92.1 or N92.4), UF only (ICD-9 218.x or ICD-10 D25.x), UF and HMB, and controls with neither condition. Baseline characteristics and treatment types (medication, surgical or procedure, or no treatment) in the year after initial diagnosis were evaluated for each group. Multivariable analyses controlling for age, region, type of insurance, total health care costs at baseline, and the Charlson Comorbidity Index were used to compare all-cause health care costs (inpatient and outpatient visits, surgeries, ER visits, and pharmacy) in the year after diagnosis between the UF and HMB cohort and the other groups.
A total of 1,149,007 women with UF and/or HMB and 2,244,368 controls were included in this study. 54.1% of those diagnosed with UF also received HMB diagnoses, and 31.3% of those diagnosed with HMB were also diagnosed with UF. In the 12 months post-diagnosis, 33.4% of those with both UF and HMB received no treatment, 25.3% underwent surgery or a procedure without medication use, 15.5% received medication only, and 25.7% underwent surgery/procedure and received medication. The average all-cause total health care costs in the group with both UF and HMB ($17,505 [$27,642]) were significantly greater than those of the women with UF only ($14,803 [$32,097]), HMB only ($10,522 [$24,912]), or the controls with neither symptom ($5,880 [$19,708]; all P<0.05).
“Among women diagnosed with both UF and HMB, mean all-cause total health care costs were significantly higher than costs for women with UF only, HMB only, and controls,” the authors of the study concluded.
This research was sponsored by AbbVie.
Wang A, Wang S, et al. Burden of Heavy Menstrual Bleeding Associated with Uterine Fibroids: A Retrospective Analysis of a Large Commercially Insured Population in the U.S. Presented at: AMCP Nexus 2019; October 29 – Nov 1; National Harbor, MD.